+

PE20181090A1 - Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 - Google Patents

Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38

Info

Publication number
PE20181090A1
PE20181090A1 PE2017002833A PE2017002833A PE20181090A1 PE 20181090 A1 PE20181090 A1 PE 20181090A1 PE 2017002833 A PE2017002833 A PE 2017002833A PE 2017002833 A PE2017002833 A PE 2017002833A PE 20181090 A1 PE20181090 A1 PE 20181090A1
Authority
PE
Peru
Prior art keywords
num
sec
ident
antibodies
treatment
Prior art date
Application number
PE2017002833A
Other languages
English (en)
Inventor
Tineke Casneuf
Henk M Lokhorst
Tuna Mutis
Tahamtan Ahmadi
Amy Sasser
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20181090A1 publication Critical patent/PE20181090A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Referido a metodos para la inmunomodulacion con anticuerpos que se unen especificamente a CD38, caracterizado porque el anticuerpo comprende la HCDR1, la HCDR2, la HCDR3, la LCDR1, la LCDR2 y la LCDR3 de: a) la VH de la sec. con num. de ident.: 14 y la VL de la sec. con num. de ident.: 15; b) la VH de la sec. con num. de ident.: 16 y la VL de la sec. con num. de ident.: 17; c) la VH de la sec. con num. de ident.: 18 y la VL de la sec. con num. de ident.: 19; d) la VH de la sec. con num. de ident.: 20 y la VL de la sec. con num. de ident.: 21. Tambien se refiere a la administracion de la cantidad terapeuticamente eficaz del anticuerpo y tratamiento de pacientes que tienen tumores solidos.
PE2017002833A 2015-06-24 2016-06-24 Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 PE20181090A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562184018P 2015-06-24 2015-06-24
US201562249546P 2015-11-02 2015-11-02
US201562250566P 2015-11-04 2015-11-04
US201562263307P 2015-12-04 2015-12-04
US201662331489P 2016-05-04 2016-05-04

Publications (1)

Publication Number Publication Date
PE20181090A1 true PE20181090A1 (es) 2018-07-09

Family

ID=57586547

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002833A PE20181090A1 (es) 2015-06-24 2016-06-24 Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38

Country Status (38)

Country Link
US (1) US20160376373A1 (es)
EP (2) EP3313441B1 (es)
JP (3) JP7041519B2 (es)
KR (2) KR102713847B1 (es)
CN (1) CN107921120A (es)
AU (1) AU2016281717B2 (es)
BR (1) BR112017027990A2 (es)
CA (1) CA2990620A1 (es)
CL (2) CL2017003275A1 (es)
CO (1) CO2017013332A2 (es)
DK (1) DK3313441T5 (es)
DO (1) DOP2017000305A (es)
EA (1) EA037548B1 (es)
EC (1) ECSP17084878A (es)
ES (1) ES2982292T3 (es)
FI (1) FI3313441T3 (es)
GT (1) GT201700286A (es)
HK (1) HK1254942A1 (es)
HR (1) HRP20240338T1 (es)
HU (1) HUE066300T2 (es)
IL (1) IL256248A (es)
LT (1) LT3313441T (es)
MA (1) MA71262A (es)
MD (1) MD3313441T2 (es)
MX (3) MX2018000261A (es)
MY (1) MY193727A (es)
NI (1) NI201700170A (es)
PE (1) PE20181090A1 (es)
PH (1) PH12017502311A1 (es)
PL (1) PL3313441T3 (es)
PT (1) PT3313441T (es)
RS (1) RS65347B1 (es)
SI (1) SI3313441T1 (es)
SM (1) SMT202400127T1 (es)
SV (1) SV2017005607A (es)
UA (1) UA124799C2 (es)
WO (1) WO2016210223A1 (es)
ZA (1) ZA201800476B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829673B2 (en) * 2005-03-23 2010-11-09 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
LT2580243T (lt) 2010-06-09 2020-01-27 Genmab A/S Antikūnai prieš žmogaus cd38
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
EP3122173B2 (en) 2014-03-26 2024-05-29 SCR Engineers Ltd Livestock location system
ME03666B (me) 2014-03-28 2020-10-20 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
US11071279B2 (en) 2014-09-05 2021-07-27 Intervet Inc. Method and system for tracking health in animal populations
US10986817B2 (en) 2014-09-05 2021-04-27 Intervet Inc. Method and system for tracking health in animal populations
PE20170676A1 (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
KR102689285B1 (ko) 2014-11-26 2024-07-31 젠코어 인코포레이티드 Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
JP2017536830A (ja) 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
PE20180671A1 (es) 2015-05-20 2018-04-19 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematologicas positivas para cd38
PE20181323A1 (es) 2015-06-22 2018-08-14 Janssen Biotech Inc Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
TWI838196B (zh) 2015-11-03 2024-04-01 美商健生生物科技公司 抗cd38抗體之皮下調配物及其用途
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108473584B (zh) 2015-11-03 2022-01-14 詹森生物科技公司 特异性结合pd-1和tim-3的抗体及其用途
WO2017100372A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
MY195089A (en) 2016-05-27 2023-01-10 Agenus Inc Anti-Tim-3 Antibodies and Methods of use thereof
EP4257613A3 (en) 2016-06-14 2023-12-13 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
JP7021127B2 (ja) 2016-06-28 2022-02-16 ゼンコア インコーポレイテッド ソマトスタチン受容体２に結合するヘテロ二量体抗体
MX2019008241A (es) * 2017-01-09 2019-12-09 Biomunex Pharmaceuticals Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
AU2018212652B2 (en) * 2017-01-26 2024-03-28 Sangamo Therapeutics, Inc. B-cell engineering
WO2018224685A1 (en) 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
KR102770104B1 (ko) * 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
WO2018224682A1 (en) 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
EP3434692A1 (en) * 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
CN111032086B (zh) 2017-08-16 2023-09-26 黑带医疗有限公司 Cd38抗体
CA3079242A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
US11832584B2 (en) 2018-04-22 2023-12-05 Vence, Corp. Livestock management system and method
JP7526717B2 (ja) 2018-07-13 2024-08-01 ジェンマブ エー／エス Ｃｄ３８抗体のバリアントおよびその使用
WO2020012038A1 (en) 2018-07-13 2020-01-16 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
AU2019351267A1 (en) * 2018-09-27 2021-05-13 Musc Foundation For Research Development Pharmaceutical combination for the treatment of cancer
IL309302B2 (en) 2018-10-10 2024-11-01 Scr Eng Ltd Livestock dry off method and device
BR112021015531A2 (pt) 2019-02-08 2021-10-26 Allflex Australia Pty Ltd Determinar a localização de um animal
WO2020160589A1 (en) 2019-02-08 2020-08-13 Allflex Australia Pty Ltd Electronic animal identification tag reader synchronisation
AU2019428486A1 (en) 2019-02-08 2021-08-26 Allflex Australia Pty Ltd Electronic animal tag reader
WO2020194241A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses
EP4090366A1 (en) 2020-01-16 2022-11-23 Genmab A/S Formulations of cd38 antibodies and uses thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
IL275518B (en) 2020-06-18 2021-10-31 Scr Eng Ltd Animal tag
USD990062S1 (en) 2020-06-18 2023-06-20 S.C.R. (Engineers) Limited Animal ear tag
USD990063S1 (en) 2020-06-18 2023-06-20 S.C.R. (Engineers) Limited Animal ear tag
IL275812B (en) 2020-07-01 2022-01-01 Scr Eng Ltd System and method for placing devices
JP2023538891A (ja) 2020-08-19 2023-09-12 ゼンコア インコーポレイテッド 抗ｃｄ２８組成物
WO2022113062A1 (en) 2020-11-25 2022-06-02 Scr Engineers Ltd. A system and method for tracing members of an animal population
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
CA3204187A1 (en) 2021-01-14 2022-07-21 Stefan Steidl Anti-cd38 antibodies and their uses
IL280374B2 (en) 2021-01-24 2023-11-01 Scr Eng Ltd System and method for controlling animal marking
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
CA206812S (en) 2021-04-08 2023-04-11 Chevillot Sas Tag applicator for animals
CA206747S (en) 2021-04-08 2024-12-30 Chevillot Sas Tag applicator for animals
CN114805582B (zh) * 2022-06-29 2022-10-04 上海恒润达生生物科技股份有限公司 抗Trop2纳米抗体及其用途
WO2024094660A1 (en) 2022-10-31 2024-05-10 Genmab A/S Cd38 antibodies and uses thereof
WO2024126750A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DE602004024041D1 (de) 2003-03-05 2009-12-24 Halozyme Inc Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
EP1720907B1 (en) 2004-02-06 2015-04-08 MorphoSys AG Anti-cd38 human antibodies and uses therefor
US7829673B2 (en) * 2005-03-23 2010-11-09 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
US20090123950A1 (en) 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
CN103554259B (zh) 2005-10-12 2016-05-18 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
WO2008073160A2 (en) * 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
ME03503B (me) * 2006-09-26 2020-04-20 Genmab As Anti-cd38 plus kortkosteroidni plus ne-kortikosteroidni hemoterapeutik za tretiranje tumora
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN101802015B (zh) 2007-03-29 2015-05-06 根马布股份公司 双特异性抗体及其制造方法
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
EP2231904B1 (en) 2007-12-19 2016-01-13 Janssen Biotech, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
EP3929216A1 (en) 2008-12-09 2021-12-29 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
CN102918058B (zh) 2009-11-24 2015-05-20 米迪缪尼有限公司 针对b7-h1的靶向结合剂
BR122021015749B1 (pt) 2010-04-20 2022-07-26 Genmab A/S Métodos in vitro para gerar uma proteína heterodimérica, para a seleção de um anticorpo biespecífico, método para produzir uma proteína heterodimérica, vetor de expressão, célula hospedeira procariótica, proteína heterodimérica, composição farmacêutica, e, uso de uma proteína heterodimérica
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
LT2580243T (lt) * 2010-06-09 2020-01-27 Genmab A/S Antikūnai prieš žmogaus cd38
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP3309175A1 (en) * 2012-05-15 2018-04-18 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9179480B2 (en) 2012-07-24 2015-11-03 Telefonaktiebolaget L M Ericsson (Publ) Apparatus and method for dynamically selecting a random access response window value for use with random access procedures in a network
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014068114A1 (en) * 2012-11-05 2014-05-08 Morphosys Ag Radiolabelled antibody and uses thereof
SG11201508923VA (en) 2013-04-29 2015-11-27 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US20140356318A1 (en) * 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
EP3004169B1 (en) 2013-05-31 2023-03-22 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
US20160235842A1 (en) * 2013-07-15 2016-08-18 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists
JP2016536361A (ja) * 2013-11-06 2016-11-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies

Also Published As

Publication number Publication date
WO2016210223A1 (en) 2016-12-29
AU2016281717B2 (en) 2022-07-28
EA201890131A1 (ru) 2018-05-31
EP3313441A4 (en) 2019-04-24
HK1254942A1 (zh) 2019-08-02
KR20180012864A (ko) 2018-02-06
CL2019003657A1 (es) 2020-05-08
MY193727A (en) 2022-10-27
GT201700286A (es) 2019-08-08
AU2016281717A1 (en) 2018-01-18
KR102713847B1 (ko) 2024-10-04
PL3313441T3 (pl) 2024-08-19
DK3313441T5 (da) 2024-10-07
DOP2017000305A (es) 2018-04-15
LT3313441T (lt) 2024-05-27
KR20240150522A (ko) 2024-10-15
PH12017502311A1 (en) 2018-06-25
JP2024153803A (ja) 2024-10-29
CN107921120A (zh) 2018-04-17
PT3313441T (pt) 2024-05-07
UA124799C2 (uk) 2021-11-24
FI3313441T3 (fi) 2024-03-28
CO2017013332A2 (es) 2018-05-21
EP3313441B1 (en) 2024-02-21
BR112017027990A2 (pt) 2018-08-28
SMT202400127T1 (it) 2024-05-14
ECSP17084878A (es) 2018-02-28
JP7532428B2 (ja) 2024-08-13
NI201700170A (es) 2019-05-10
SI3313441T1 (sl) 2024-05-31
EP4385569A3 (en) 2024-09-25
HUE066300T2 (hu) 2024-07-28
JP7041519B2 (ja) 2022-03-24
MA71262A (fr) 2025-04-30
MD3313441T2 (ro) 2024-08-31
MX2021012133A (es) 2021-11-03
ES2982292T3 (es) 2024-10-15
MX2021012134A (es) 2021-11-03
SV2017005607A (es) 2019-03-28
EP3313441A1 (en) 2018-05-02
US20160376373A1 (en) 2016-12-29
CL2017003275A1 (es) 2018-04-20
JP2022070892A (ja) 2022-05-13
IL256248A (en) 2018-02-28
RS65347B1 (sr) 2024-04-30
EA037548B1 (ru) 2021-04-12
HRP20240338T1 (hr) 2024-05-24
CA2990620A1 (en) 2016-12-29
EP4385569A2 (en) 2024-06-19
DK3313441T3 (da) 2024-04-15
ZA201800476B (en) 2021-05-26
JP2018527299A (ja) 2018-09-20
MX2018000261A (es) 2018-03-08

Similar Documents

Publication Publication Date Title
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
JP2015530399A5 (es)
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
NZ731735A (en) Anti-pd-1 antibodies and methods of use thereof
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
RU2015110981A (ru) Комбинации и их применение
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20170935A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
PE20190630A1 (es) Anticuerpos de anti-tim-3
MX389805B (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
DOP2016000133A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
AR096687A1 (es) Anticuerpos anti-fcrh5
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
PE20170953A1 (es) ANTICUERPOS ANTI-CD79b Y METODOS DE USO
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载